Replies to post #752961 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Thanks to both you and lykiri for working together to resolve that question mark.

[dennisdave]

In this case, there were 7 months in between the first meeting and the second, rather than the 6 which is more common.

as of today, we are 253 days after the first CHM meeting so 8.3 months after the first DCVAXL CHM meeting

6 months is common, 7 months happens. we are now starting to travel into uncomfortable territory imo

[StonkMaster]

Triple combination medicine deutivacaftor/tezacaftor/vanzacaftor approved for cystic fibrosis

https://www.gov.uk/government/news/triple-combination-medicine-deutivacaftortezacaftorvanzacaftor-approved-for-cystic-fibrosis?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=c85bfc28-e366-4e5a-844b-54f08286b6d6&utm_content=immediately

[Lykiri]

It first appeared in the minutes for the February 22 2024 meeting:

a medicine used in combination with platinum-based chemotherapy indicated for the first-line treatment of adults with metastatic non-small-cell lung cancer caused by changes in a gene called ‘EGFR’ (Epidermal Growth Factor receptor).

tunnelvisionofplenty,

I believe the February 2024 meeting referred to a different medicine: Osimertinib. Osimertinib is a highly selective and irreversible EGFR inhibitor that targets activating sensitizing EGFR mutations (EGFRm+) as well as the T790M resistance mutation. It is used in combination with platinum-based chemotherapy for the first-line treatment of adults with advanced non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 (L858R) substitutions. Clinical trials showed it significantly improved progression-free survival. It was approved in September 2024. The medicine approved yesterday, Lazertinib, is also an EGFR inhibitor, but it is used with Amivantamab, which works through a different mechanism.

From NICE:

Osimertinib is indicated in combination with pemetrexed and
platinum-based chemotherapy for the first-line treatment of adult
patients with advanced NSCLC whose tumours have EGFR exon 19
deletions or exon 21 (L858R) substitution mutations.
• Marketing authorisation was granted in September 2024